Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 3, 2026 · Other material event · Financial statements
TG THERAPEUTICS, INC.
8
Other material event
Jun 3, 2026
| Item 8.01 | Other events the company considers material |
| Item 9.01 | Financial statements and exhibits |
TG THERAPEUTICS, INC. filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. 1 TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI ® (ublituximab-xiiy) Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027 Novel Investigational high co…
This filing reports Item 8.01 (other events the company considers material). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
TG THERAPEUTICS, INC. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
